Dr. Lal Path Labs valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Price multiples — at each FY-end close
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
59.13×————
12.77×————
11.08×————
69.31×————
Enterprise multiples
10.86×————
37.49×————
47.15×————
Yield
1.7%————
1.4%————
Reference — adjusted share basis
₹1,911.70————
₹32.33₹30.12₹29.06₹21.34₹14.25
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

LALPATHLAB₹1,911.70

Dr. Lal Path Labs Ltd.

· Pharma & Health
₹ CrorePeersMETROPOLISVIJAYATHYROCARENATCOPHARMNEULANDLABNHCOHANCESAILIFEMcap ₹32,040 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————59.13
P/B————12.77
P/Sales————11.08
Price to Free Cash Flow————69.31
Enterprise Multiples
EV/Sales————10.86
EV/EBITDA————37.49
EV/EBIT————47.15
Yield
Earnings Yield %————1.69
FCF Yield %————1.44
Reference — adjusted share basis
Price (FY-end close, adj.)————1,911.70
EPS (adj.)14.2521.3429.0630.1232.33
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.